Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I think RG anticipates a higher share price.

Probably a question for Fut. But if you use T shares to acquire an entity, presumably an entity that you expect to create earnings for your company, doesn't that merged entity remain on the books at a value?

Share
New Message
Please login to post a reply